None listed
Conditions
Interventions
Biological/Vaccine, Non-Stem Cell : CellgramDC-WT1, a dendritic cell derived from autologous bone marrow, is administered to metastatic pancreatic cancer patients who have failed at least one standa
Sponsors
Soon Chun Hyang University Hospital Seoul
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) 19 or older and under 80 (2) Patients diagnosed histologically with pancreatic cancer, recurrent, metastatic (3) Patients confirmed to have progressed the disease in accordance with RECIST v1.1 after standard chemotherapy of primary or higher (4) Patients who meet full-body performance status ECOG 0-2 (5) Patients with at least one measurable lesion according to RECIST v1.1 (6) Patients who have not received surgery, radiotherapy, or immunotherapy within the past 4 weeks and have recovered from side effects (However, tissue collection procedures that do not affect the condition of the subject are allowed at the discretion of the researcher) (7) Patients who agreed to use medically recognized contraception during the clinical study participation period (8) Patients who can conduct clinical research in accordance with the clinical research plan (9) Patients who have agreed in writing to participate in this clinical study voluntarily
Exclusion criteria
Exclusion criteria: (1) Patients with malignant tumors other than non-melanoma skin cancer in the last 3 years (2) Patients who have previously received anti-tumor immunotherapy (such as anti-PD1, anti-PDL-1 or CTLA4 inhibitor) or participated in clinical studies related to immunotherapy or cell therapy (3) Patients with active autoimmune diseases requiring systemic immunosuppression therapy (4) a patient with a history of organ or hematopoietic stem cell transplantation (5) Patients with acute or chronic infections requiring systemic treatment (6) a patient known to be positive for human immunodeficiency virus (HIV) infection/serum (7) Patients with active hepatitis A, B or C (8) an untreated syphilis patient (9) Patients who received a live virus vaccine (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, BCG, oral typhoid vaccine, Flu-Mist, etc.) within 30 days (10) Pregnant or breastfeeding patient (11) In addition, if the Tester deems that he/she is not suitable for clinical research
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| efficacy | — |
Countries
Korea, Republic of
Contacts
Public ContactKyoung Ha Kim
Soon Chun Hyang University Hospital Seoul
Outcome results
None listed